Treatment of patients with relapsed or refractory primary CNS lymphoma (rrPCNSL) enrolled in the randomized trials of the international extranodal lymphoma study group (IELSG)
Authors
Ferreri, A. J. M.Cwynarski, K.
Pulczynski, E.
Fox, C. P.
La Rosee, P.
Schorb, E.
Krampera, M.
Ilariucci, F.
Orsucci, L.
Fabbri, A.
Tucci, A.
Roeth, A.
Linton, Kim M
Binder, M.
Hemmaway, C.
Cabras, M. G.
Pinto, A.
Calimeri, T.
Cavalli, F.
Zucca, E.
Illerhaus, G.
Affiliation
IRCCS San Raffaele Scientific Institute, Milano, ItalyIssue Date
2021
Metadata
Show full item recordCitation
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, La Rosee P, Schorb E, et al. Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG). Blood. 2021 Nov;138. PubMed PMID: WOS:000736398805144.Journal
BloodDOI
10.1182/blood-2021-147822Additional Links
https://dx.doi.org/10.1182/blood-2021-147822Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-147822